Our results from AML and T-NHL were mostly negative for ROR1 protein levels via IHC, so a more restrictive v1-specific anti-ROR1 Ab will not change the IHC prevalence data presented here for these two indications. Here, ROR1 is linked to non-Hodgkin lymphoma.